Navigation Links
Well-informed patients key to accepting gene-based drug dosing
Date:4/28/2014

A new study out of Western University (London, Canada) illustrates the need for a lot more education around pharmacogenetics (PGx) the study of how a patient's genes can affect drug reaction and dosage. PGx promises to optimize patient response to therapy, but this is the first study to really investigate how patients perceive this kind of genetic testing, and whether those perceptions differ when it comes to parents and their children. The research, led by Dr. Michael Rieder of Western's Schulich School of Medicine & Dentistry is published in the journal Pediatrics.

"Pharmacogenetic testing has become widely used and gene-based drug dosing is becoming a reality for a number of common health problems. This study confirms what we suspected; Whether or not you're a parent, your degree of acceptability of genetic testing was determined by your knowledge of it. That is to say if you understand what the test is for, and the concept of gene-based drug dosing, you're far more open to it, than if you don't understand it," said Dr. Rieder, a professor in the Departments of Paediatrics, and Physiology and Pharmacology.

The researchers surveyed three groups including: 236 medical students representing those having greater educational exposure to PGx, 1,226 lay parents and 105 lay people without children. A second survey was completed by 229 parents. The surveys didn't use PGx but rather, asked about "DNA testing to guide therapy." The study concluded that the acceptability of PGx testing, either for oneself or one's child, seemed to depend on baseline PGx knowledge, but not on parenthood.

The main concern for all respondents was the need for informed consent. Other findings included:

  • More acceptance for PGx when the disease was severe

  • Strong desire/demand for separate consent for PGx testing

  • More education about PGx needed in medical schools

  • Acceptability of genetic testing didn't differ whether for the parent or the child

Dr. Rieder says PGx should take a lesson from pediatric oncology. He says health care workers in that division do a good job in the way they frame the discussions around care, treatment, and consent. "When they have to make a diagnosis, they spend a lot of time explaining what tests they're going to do, the risks, and what therapies are available. And they're successful. Their patients comply with treatment, they get involved in studies, they're informed, and they want to know what's going on."


'/>"/>
Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert  

Related biology news :

1. Breast cancer patients place huge emphasis on gene expression profiling test
2. Spinal stimulation helps 4 patients with paraplegia regain voluntary movement
3. Key genetic mutations could be new hope for adrenocortical tumor patients
4. Cause for exaggerated insulin response in subset of bariatric surgery patients identified
5. Faster genetic testing method will likely transform care for patients with breast cancer
6. Certain genetic variants may put bladder cancer patients at increased risk of recurrence
7. How the science of deer hunting can help patients with diabetes
8. Diaphragm pacing in spinal cord injury successful in weaning patients from ventilators
9. Vitamin A used in acne medicines may help autoimmune and transplant patients
10. Gastric banding patients should closely monitor nutrition following surgery
11. Identified a subgroup of schizophrenia patients with motor disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Well-informed patients key to accepting gene-based drug dosing
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/2/2017)...  EyeLock LLC, a market leader of iris-based identity ... What You Should Know About Biometrics in the Cloud ... is a growing concern. In traditional schemes, cryptography is ... authentication schemes such as username/password suffer from inherent weaknesses. ... an elegant solution to the problem of high-security user ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... protect and restore the health of patients, intends to report operational ... on Thursday, March 2, 2017, and to host a conference call ... the call is as follows: U.S. (toll free): 1-888-347-5280 ... ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Trevor Heritage has joined its executive team to lead the development and commercialization ... insights to help improve the diagnosis and treatment of cancer. The CIDT addresses ...
(Date:2/21/2017)... and VANCOUVER, British Columbia , Feb. ... ) today announced that apatorsen results from two randomized Phase ... Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held February 16 ... . Clinical data from trials in bladder and prostate cancers ... in combination with standard-of-care treatments. ...
(Date:2/21/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Bioplastics & Biopolymers Market ... the next decade to reach approximately $8.9 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology Technology: